Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia

Hermann L. Müller, Youngman Oh, Sharron E. Gargosky, Kristin F. Wilson, Thomas Lehrnbecher, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is IGFBP-3. We investigated whether sera from children with malignancies show alterations in levels of IGFBP-3 as measured by Western ligand blot analysis (WLB) and RIA with aIGFBP-3gl, a specific rabbit polyclonal antibody. Furthermore, IGFBP-3 proteolysis was quantified by densitometric analysis of [125I]IGFBP-3 protease assays, and IGFBP-3 fragments were visualized by Western immunoblot with αIGFBP-3gl. We examined sera from 21 children with solid tumors, five patients with sarcoma who had reached complete remission, and 13 children with acute leukemia. Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy children served as normal controls. Children with solid tumor or leukemia had significantly higher (p <0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. Corresponding to this finding, densitometry of WLB showed lower IGFBP-3 levels in sera of children with malignancies in comparison with normal controls. The negative correlation (p <0.001, r = —0.80) between IGFBP-3 proteolysis, as measured by [125I]IGFBP-3 protease assay, and IGFBP-3 band density on WLB indicates that proteolysis is the probable reason for reduction of IGFBP-3 on WLB. IGFBP-3 concentrations measured by RIA were in the normal range for most patients, further indicating that differences in serum IGFBP-3 levels measured by WLB reflect protease activity. We conclude that sera from children with malignancies frequently contain protease activity that causes IGFBP-3 cleavage in a way that might affect the tissue availability of IGF. Because many tumor cells are responsive to the mitogenic actions of IGF in vitro, IGFBP-3 proteases in serum could also play a role in tumor progression and metastasis in vivo.

Original languageEnglish (US)
Pages (from-to)720-724
Number of pages5
JournalPediatric Research
Volume35
Issue number6
StatePublished - 1994
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Leukemia
Serum
Neoplasms
Peptide Hydrolases
Western Blotting
Insulin-Like Growth Factor Binding Proteins
Ligands
Proteolysis
insulin-like growth factor binding protein-3 protease
Sarcoma
Densitometry

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia. / Müller, Hermann L.; Oh, Youngman; Gargosky, Sharron E.; Wilson, Kristin F.; Lehrnbecher, Thomas; Rosenfeld, Ronald (Ron).

In: Pediatric Research, Vol. 35, No. 6, 1994, p. 720-724.

Research output: Contribution to journalArticle

Müller, Hermann L. ; Oh, Youngman ; Gargosky, Sharron E. ; Wilson, Kristin F. ; Lehrnbecher, Thomas ; Rosenfeld, Ronald (Ron). / Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia. In: Pediatric Research. 1994 ; Vol. 35, No. 6. pp. 720-724.
@article{bbbe2cc3113a4afaad71f148e0de9151,
title = "Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia",
abstract = "IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is IGFBP-3. We investigated whether sera from children with malignancies show alterations in levels of IGFBP-3 as measured by Western ligand blot analysis (WLB) and RIA with aIGFBP-3gl, a specific rabbit polyclonal antibody. Furthermore, IGFBP-3 proteolysis was quantified by densitometric analysis of [125I]IGFBP-3 protease assays, and IGFBP-3 fragments were visualized by Western immunoblot with αIGFBP-3gl. We examined sera from 21 children with solid tumors, five patients with sarcoma who had reached complete remission, and 13 children with acute leukemia. Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy children served as normal controls. Children with solid tumor or leukemia had significantly higher (p <0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. Corresponding to this finding, densitometry of WLB showed lower IGFBP-3 levels in sera of children with malignancies in comparison with normal controls. The negative correlation (p <0.001, r = —0.80) between IGFBP-3 proteolysis, as measured by [125I]IGFBP-3 protease assay, and IGFBP-3 band density on WLB indicates that proteolysis is the probable reason for reduction of IGFBP-3 on WLB. IGFBP-3 concentrations measured by RIA were in the normal range for most patients, further indicating that differences in serum IGFBP-3 levels measured by WLB reflect protease activity. We conclude that sera from children with malignancies frequently contain protease activity that causes IGFBP-3 cleavage in a way that might affect the tissue availability of IGF. Because many tumor cells are responsive to the mitogenic actions of IGF in vitro, IGFBP-3 proteases in serum could also play a role in tumor progression and metastasis in vivo.",
author = "M{\"u}ller, {Hermann L.} and Youngman Oh and Gargosky, {Sharron E.} and Wilson, {Kristin F.} and Thomas Lehrnbecher and Rosenfeld, {Ronald (Ron)}",
year = "1994",
language = "English (US)",
volume = "35",
pages = "720--724",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Insulin-like growth factor binding protein-3 concentrations and insulin-like growth factor binding protein-3 protease activity in sera of patients with malignant solid tumors or leukemia

AU - Müller, Hermann L.

AU - Oh, Youngman

AU - Gargosky, Sharron E.

AU - Wilson, Kristin F.

AU - Lehrnbecher, Thomas

AU - Rosenfeld, Ronald (Ron)

PY - 1994

Y1 - 1994

N2 - IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is IGFBP-3. We investigated whether sera from children with malignancies show alterations in levels of IGFBP-3 as measured by Western ligand blot analysis (WLB) and RIA with aIGFBP-3gl, a specific rabbit polyclonal antibody. Furthermore, IGFBP-3 proteolysis was quantified by densitometric analysis of [125I]IGFBP-3 protease assays, and IGFBP-3 fragments were visualized by Western immunoblot with αIGFBP-3gl. We examined sera from 21 children with solid tumors, five patients with sarcoma who had reached complete remission, and 13 children with acute leukemia. Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy children served as normal controls. Children with solid tumor or leukemia had significantly higher (p <0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. Corresponding to this finding, densitometry of WLB showed lower IGFBP-3 levels in sera of children with malignancies in comparison with normal controls. The negative correlation (p <0.001, r = —0.80) between IGFBP-3 proteolysis, as measured by [125I]IGFBP-3 protease assay, and IGFBP-3 band density on WLB indicates that proteolysis is the probable reason for reduction of IGFBP-3 on WLB. IGFBP-3 concentrations measured by RIA were in the normal range for most patients, further indicating that differences in serum IGFBP-3 levels measured by WLB reflect protease activity. We conclude that sera from children with malignancies frequently contain protease activity that causes IGFBP-3 cleavage in a way that might affect the tissue availability of IGF. Because many tumor cells are responsive to the mitogenic actions of IGF in vitro, IGFBP-3 proteases in serum could also play a role in tumor progression and metastasis in vivo.

AB - IGF binding proteins (IGFBP) regulate the bioavailability and bioactivity of IGF. The major IGFBP in serum is IGFBP-3. We investigated whether sera from children with malignancies show alterations in levels of IGFBP-3 as measured by Western ligand blot analysis (WLB) and RIA with aIGFBP-3gl, a specific rabbit polyclonal antibody. Furthermore, IGFBP-3 proteolysis was quantified by densitometric analysis of [125I]IGFBP-3 protease assays, and IGFBP-3 fragments were visualized by Western immunoblot with αIGFBP-3gl. We examined sera from 21 children with solid tumors, five patients with sarcoma who had reached complete remission, and 13 children with acute leukemia. Serum samples were collected at diagnosis, before initiation of therapy. Sera of 10 healthy children served as normal controls. Children with solid tumor or leukemia had significantly higher (p <0.001) IGFBP-3 protease activity in serum than did normal controls or patients with sarcoma in complete remission. Corresponding to this finding, densitometry of WLB showed lower IGFBP-3 levels in sera of children with malignancies in comparison with normal controls. The negative correlation (p <0.001, r = —0.80) between IGFBP-3 proteolysis, as measured by [125I]IGFBP-3 protease assay, and IGFBP-3 band density on WLB indicates that proteolysis is the probable reason for reduction of IGFBP-3 on WLB. IGFBP-3 concentrations measured by RIA were in the normal range for most patients, further indicating that differences in serum IGFBP-3 levels measured by WLB reflect protease activity. We conclude that sera from children with malignancies frequently contain protease activity that causes IGFBP-3 cleavage in a way that might affect the tissue availability of IGF. Because many tumor cells are responsive to the mitogenic actions of IGF in vitro, IGFBP-3 proteases in serum could also play a role in tumor progression and metastasis in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0028334159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028334159&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 720

EP - 724

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -